primary%20open-angle%20glaucoma
PRIMARY OPEN-ANGLE GLAUCOMA
Primary open-angle glaucoma (POAG) is a chronic, progressive, usually bilateral disease of the eye with an insidious onset.
It is most often characterized by optic nerve damage, defects in the retinal fiber layer and subsequent visual field loss in the absence of underlying ocular disease or congenital abnormalities.
It is generally asymptomatic until it has caused a significant loss of visual field.
Occasionally, patients with very high intraocular pressure may complain of nonspecific headache, discomfort, intermittent blurring of vision or even halos caused by corneal edema.

Patient Education

  • Inform and involve patients about the status of their condition, the goals and plans for managing their disease, as well as the risks and benefits involved in such interventions
  • Form a therapeutic alliance with patient and family, and stress that glaucoma is a chronic disease where treatment and follow-up is life-long
  • Educate patients on how to recognize significant changes in their condition so physicians may be alerted
  • Provide emotional support and encouragement to help patients deal with possible issues concerning employment, relationships, diminished functional capacities (eg driving, reading, performance of everyday tasks, sports-related activities)
    • Patients may be referred to support groups or provided counseling
  • Patients should be taught how to perform nasolacrimal occlusion or eyelid closure when applying topical medications to reduce systemic absorption
    • Punctual occlusion and eyelid closure for at least 3 minutes
    • If ≥2 drops are to be instilled, wait at least 5 minutes between drops
Editor's Recommendations
Most Read Articles
4 days ago
Older women with longer endogenous oestrogen exposure and hormone therapy use are at much higher odds of having favourable cognitive status in late life, a recent study suggests.
2 days ago
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Elvira Manzano, 3 days ago
Supplementation with omega-3 fatty acids or vitamin D3 for up to 5 years has no effect on kidney function in adults with type 2 diabetes (T2D), the VITAL-DKD* ancillary study has shown.
Jairia Dela Cruz, 17 hours ago
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.